Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 6/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23796197 | 0.87 | MAPT (0.43) | KDM4EPSMD14RXRAMGAMPOLB | |
| SCHEMBL23795961 | 0.87 | PSMD14 (0.50) | KDM4EPSMD14HPGDSHDAC3HDAC1 | |
| SCHEMBL23796031 | 0.83 | EGLN1 (0.52) | KDM4EPSMD14MGAMHDAC3HDAC1 | |
| SCHEMBL23796443 | 0.82 | KMT2A (0.40) | KDM4EPSMD14CHEK1NTRK2MGAM | |
| SCHEMBL23796189 | 0.82 | HPGDS (0.60) | HPGDSHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL19783646 | 0.80 | ALDH1A1 (0.40) | — | |
| SCHEMBL23796337 | 0.80 | PSMD14 (0.45) | KDM4EPSMD14MGAMCA1CA2 | |
| SCHEMBL19783129 | 0.78 | CYP11B1 (0.40) | KDM4EHDAC6 | |
| SCHEMBL28630897 | 0.77 | HPGDS (0.48) | HPGDSHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL28630896 | 0.77 | HPGDS (0.48) | HPGDSHDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIOVENTURES, INC., | 2025-07-10 | — | — | US | disclosed |
| CN-119522215-A | TEAD inhibitors and methods of use | 思博睿生物探索公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4496789-A1 | TEAD INHIBITORS AND METHODS OF USE | Sporos Biodiscovery, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023183437-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183437-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-3877356-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-113302175-A | Bicyclic compounds | 维瓦斯治疗公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223306-A1 | TEAD INHIBITORS AND METHODS OF USE | TEAD1, TEAD2, TEAD3 | KDM4E 2093/4885PSMD14 2590/4885CHEK1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.